Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or ...

The Fukushima Daiichi nuclear power plant's radiation levels have significantly dropped since the cataclysmic meltdown in ...

Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...